Skip to Main Content

Nuclear Medicine and Molecular Imaging: Therapy & Dosimetry

Therapy & Dosimetry Resources

Common Terminology Criteria for Adverse Events (CTCAE)

Therapy and Dosimetry (General)

Beylergil V., et al. (2013) A Historical Perspective on the Use of Radionuclides for Therapy. In: Baum R. (eds) Therapeutic Nuclear Medicine. Medical Radiology. Springer, Berlin, Heidelberg.

Gomes Marin JF, et al. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics. 2020 Oct;40(6):1715-1740.

Iodine-131 Thyroid Cancer

Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133.

Francis GL, et al; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 Jul;25(7):716-59.

Oh JR, Ahn BC. False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer. Am J Nucl Med Mol Imaging. 2012;2(3):362-85.

Iodine-131 Hyperthyroidism

Ross DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016 Oct;26(10):1343-1421.

Silberstein EB, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med. 2012 Oct;53(10):1633-51.

Rivkees SA. Pediatric Grave's Disease: Controversies in Management. Horm Res Paediatr. 2010;74(5):305-311.

Iodine-131 iobenguane (Azedra) 

Highlights of Prescribing Information (Package Insert)

Lutetium-177 dotatate (Lutathera)

Highlights of Prescribing Information (Package Insert)

Burkett BJ, et al. How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology. 2021 Feb;298(2):261-274.

Bellizzi AM. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am. 2020 Apr;29(2):185-208.

Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018;59(1):66-74. doi:10.2967/jnumed.117.202275 

Pencharz D, Gnanasegaran G, Navalkissoor S. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. Br J Radiol. 2018;91(1091):20180108. doi:10.1259/bjr.20180108

Lutetium-177 PSMA (Pluvicto)

Highlights of Prescribing Information (Package Insert)

Sartor O, Herrmann K. Prostate Cancer Treatment: 177Lu-PSMA-617 Considerations, Concepts, and Limitations. J Nucl Med. 2022 Jun;63(6):823-829.

Vorster M, Sathekge MM. Theranostics in Metastatic Castrate Resistant Prostate Cancer. In: Bott SRJ, Ng KL, eds. Prostate Cancer. Exon Publications; 2021. Accessed February 1, 2023. ISBN: 978-0-6450017-5-4.

Radium-223 chloride (Xofigo)

Highlights of Prescribing Information (Package Insert)

Yttrium-90 microspheres (SirTex and Theraspheres)

Lee EJ, Chung HW, Jo JH, So Y. Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. Nucl Med Mol Imaging.2019 Dec;53(6):367-373. doi: 10.1-019-00615-9.007/s13139

Busse NC, Al-Ghazi MSAL, Abi-Jaoudeh N, Alvarez D, Ayan AS, Chen E, Chuong MD, Dezarn WA, Enger SA, Graves SA, Hobbs RF, Jafari ME, Kim SP, Maughan NM, Polemi AM, Stickel JR. AAPM Medical Physics Practice Guideline 14.a: Yttrium-90 microsphere radioembolization. J Appl Clin Med Phys. 2023 Oct 11:e14157.